Novartis’ Annemarie Hanekamp heads to BioNTech

20 March 2024
230218-annemarie-hanekamp-2-1-

Germany’s BioNTech (Nasdaq: BNTX) has announced the appointment of Annemarie Hanekamp (pictured, above) as the company’s new chief commercial officer, succeeding Sean Marett.

Ms Hanekamp - a seasoned pharma executive experienced in developing patient-focused commercial strategies for innovative oncology products encompassing sales, marketing and market access - joins from Novartis (NOVN: VX), where she headed global radioligand therapy for the Swiss pharma giant.

"An accomplished leader with a track record of more than a dozen successful product launches"In her new role, Ms Hanekamp will drive and execute BioNTech’s global commercialization strategy, tasked with realizing the firm’s full potential as a vertically integrated biopharmaceutical company.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology